Marble Harbor Investment Counsel LLC Buys 179 Shares of Johnson & Johnson (NYSE:JNJ)

Marble Harbor Investment Counsel LLC lifted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 0.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,677 shares of the company’s stock after buying an additional 179 shares during the period. Johnson & Johnson comprises 1.5% of Marble Harbor Investment Counsel LLC’s portfolio, making the stock its 23rd biggest holding. Marble Harbor Investment Counsel LLC’s holdings in Johnson & Johnson were worth $9,706,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. RE Dickinson Investment Advisors LLC raised its position in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares in the last quarter. Morton Brown Family Wealth LLC raised its position in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Advanced Research Investment Solutions LLC raised its position in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares in the last quarter. Professional Financial Advisors LLC raised its position in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares in the last quarter. Finally, Goodman Advisory Group LLC acquired a new position in Johnson & Johnson in the second quarter worth about $39,000. Institutional investors own 68.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Barclays began coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Bank of America dropped their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a report on Wednesday, October 19th. Raymond James dropped their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.33.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,707,775. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the transaction, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 212,646 shares of company stock valued at $36,791,022. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $177.01 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The firm has a market cap of $462.79 billion, a P/E ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. The firm has a 50 day simple moving average of $168.35 and a 200 day simple moving average of $171.28. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same quarter last year, the business posted $2.60 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a yield of 2.55%. Johnson & Johnson’s payout ratio is presently 62.95%.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase program on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.